key: cord-0716531-tjq6fvf5
authors: Shroff, Hersh; Satapathy, Sanjaya K.; Crawford, James M.; Todd, Nancy J.; VanWagner, Lisa B.
title: Liver injury following SARS-CoV-2 vaccination: a multicenter case series
date: 2021-07-31
journal: J Hepatol
DOI: 10.1016/j.jhep.2021.07.024
sha: e72e0d71f6aec431fe22f54b2961fad0b4c269c3
doc_id: 716531
cord_uid: tjq6fvf5

nan

Abbreviations: AASLD: American Association for the Study of Liver Disease; AIH: autoimmune hepatitis; ALF: acute liver failure; ALI: acute liver injury; ALT: alanine aminotransferase; ANA, anti-nuclear antibody; AP, alkaline phosphatase; ASMA, anti-smooth muscle antibody; AST: American Society of Transplantation; COVID-19: coronavirus disease 2019; DILI, drug-induced liver injury; EBV, Epstein-Barr virus; ERCP: endoscopic retrograde cholangiopancreatogram; F, female; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; IAIHG: international autoimmune hepatitis group; IgG: immunoglobulin G; IgM, immunoglobulin M; INR: international normalized ratio; IRB: institutional review board; ITP: immune thrombocytopenia; LICOP: liver and intestinal community of practice; M, male; mRNA: messenger RNA; MRCP: magnetic resonance cholangiopancreatogram; NAC: N-acetylcysteine; NAFLD, non-alcoholic fatty liver disease; NSAID: non-steroidal anti-inflammatory drug; PSC: primary sclerosing cholangitis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; UTI, urinary tract infection; VCA, viral capsid antigen; VZV, varicella zoster virus.

To the editor:

In response to the COVID-19 pandemic, two novel mRNA-based vaccinations against the SARS-CoV-2 virus have been manufactured and distributed in an unprecedented fashion. In light of their rapid uptake, providers must remain vigilant for new adverse events. In early 2021, multiple providers, communicating on AST LICOP and AASLD online forums, shared strikingly similar experiences with patients who presented with liver injury following COVID vaccination with no other clear precipitants. Given the pattern, we report herein on a multicenter cohort of patients with liver injury following COVID vaccination. No personally-identifiable information or protected health information was collected for any patient. The series was reviewed by the Northwestern University IRB and deemed not to be human subjects research.

Our cohort includes 16 total patients ( Table 1 ) ages 25 to 74, who presented between 5 to 46 days following their first vaccine dose (Pfizer: 12, Moderna: 4). Notably, 75% of patients (12/16) presented after their second vaccine dose.

Six patients had a history of chronic liver disease, including four (#6, 10, 11, 13) with AIH in treated remission (i.e., no medication changes or abnormal labs for a minimum of six months). Three patients had cirrhosis: two AIH patients (#10 and 11) and one with previously-treated HCV (#4).

The majority (13/16) of cases demonstrated a hepatocellular pattern of liver injury (peak ALT: 96 to >5000 U/L). Of the remaining three cases, one (#4) was cholestatic and two (#12, 16) were mixed. ALI (defined as INR > 1.5) occurred in 3 patients (#9, 14, and 15; INR range 2.2 to 5.5); no patients developed ALF.

Patient #1 was diagnosed with "new" sclerosing cholangitis via ERCP on this presentation; however, on chart review, he presented with DILI (amoxicillin) two years earlier at which time an MRCP had subtle non-diagnostic biliary findings, raising in retrospect the possibility of undiagnosed PSC. At the time of presentation, the DILI was long-since resolved, and the current presentation appears to represent an ALI event in a patient with pre-existing cholangitis. Patient #2 had been prescribed a three-day course of nitrofurantoin approximately 90 days prior to presentation. The scenario was deemed atypical for nitrofurantoin toxicity (particularly the short exposure and clinical presentation). Patients #3 and #7 used ibuprofen immediately following the second vaccine dose (two to three days total, unknown total doses); patient #15 reported chronic acetaminophen use (3-4 grams for several days per week over the preceding year); and patient #16 had knee surgery three days prior to presentation and used alternating acetaminophen and acetaminophen-hydrocodone for a total of four days. None of these were deemed likely to be causative given the time frame and short exposures. No patient displayed laboratory evidence of viral hepatitis, and all patients tested negative for COVID infection. While seven of the 12 patients without previously known AIH had at least one positive autoimmune marker at the time of presentation, only one (#15) met IAIHG simplified criteria for "probable" AIH (ANA 1:640, elevated IgG to 1,750 mg/dL, and biopsy "compatible" with AIH). 1 10/16 patients underwent liver biopsy (Table 1) . All exhibited portal inflammation (60% graded as moderate or severe). Five cases demonstrated a significant plasma cell component (of whom #10, 11, and 13 had pre-existing AIH and displayed interface activity), all of whom received prednisone. Cholestasis and bile duct reaction, though variably present, were only prominent in one case (#16) with severe cholestasis and minimal inflammation. Excluding patients with known cirrhosis (n=3), significant fibrosis was not seen in any patient. 10/16 patients required hospitalization. In total, six of 16 patients required no treatment. Of the 10 who received treatment, two (#9, 14; both with ALI) received NAC infusions, and eight (see Table 1 ) received steroids. Patient #1, newly diagnosed with sclerosing cholangitis, underwent biliary dilatation. Importantly, all patients recovered or were recovering from the acute event at the time of assembling our cohort.

We acknowledge that our series of patients with hepatic injury following mRNA-based COVID vaccination contains retrospective and observational data without adjudication. Thus, our report is not structured to evaluate potential causality. In our patients with prior drug exposure (amoxicillin; nitrofurantoin; NSAIDs, acetaminophen), the exposures were either too short or the presentations highly atypical (by laboratory data or histopathology) to be attributed solely to the medication. Thus, DILI is not readily implicated in this patient series, although it cannot be wholly excluded. We also consider unlikely direct hepatotoxicity from SARS-CoV-2 mRNA vaccines, noting the strong safety profile for delivery of lipid nanoparticle mRNA vaccines to human tissues. 2 Rather, vaccine-induced immune-mediated hepatitis is a known phenomenon, [3] [4] and other autoimmune events (e.g., AIH, ITP) have been reported following COVID vaccination. [5] [6] It is plausible that a similar mechanism is occurring here, whereby the host immune response directed against the COVID spike protein triggers an aberrant, autoimmune-like hepatitic condition in predisposed individuals. Many questions still remain. In particular, should patients at higher risk of hepatic autoimmunity (e.g., existing AIH, post-liver transplant) undergo pre-emptive laboratory monitoring post-vaccination? Will there be safety concerns for these patients if booster doses are recommended in the future?

We emphasize that our intent is not to promote vaccine hesitancy. The overwhelming benefits of these and other highly efficacious vaccines in the setting of a global pandemic greatly surpass any potential risk of liver injury that may exist. We simply aim to share a clinical scenario that has been observed independently by multiple providers at various institutions, with the hope that as vaccine uptake continues to increase, our shared experience can help in early recognition, further study, and management of potential adverse events.

J o u r n a l P r e -p r o o f 

Simplified Criteria for the Diagnosis of Autoimmune Hepatitis

The nanomedicine rush: New strategies for unmet medical needs based on innovative nano DDS

Autoimmune hepatitis developing after coronavirus disease 2019 (COVID-19) Vaccine: Causality or casualty?

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

Hepatitis A vaccine associated with autoimmune hepatitis

Vaccination as a triggering event for autoimmune hepatitis

Data transparency: Data and study materials will not be made available to other researchers.

Hersh Shroff (conceptualization, methodology, visualization, writing original draft, writing review and editing) Sanjaya K. Satapathy (visualization, resources, writing review and editing) James M. Crawford (visualization, resources, writing review and editing) Nancy J. Todd (resources, writing review and editing) Lisa B. VanWagner (conceptualization, methodology, resources, supervision, visualization, writing review and editing)

J o u r n a l P r e -p r o o f